DWTX
Dogwood Therapeutics, Inc.·Healthcare
1.99
0.505%(+0.01)
Market ClosedLast Updated: — ET
52W L: $1.7752W H: $9.50
DWTX NEWS
defenseworld.net
Apr 1
Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX)
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Analyst Recommendations This is a summary of recent
defenseworld.net
Mar 23
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday
Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the
globenewswire.com
Mar 18
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025.
defenseworld.net
Mar 14
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?
Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day trading on Friday. The company traded as high as $3.17 and last traded at $3.06. Approximately 49,806 shares traded hands during trading, an increase of 47% from the average daily volume of 33,985 shares. The stock had previously closed
globenewswire.com
Feb 2
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.
defenseworld.net
Jan 16
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Expands By 61.2%
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 81,743 shares, an increase of 61.2% from the December 15th total of 50,720 shares. Approximately 3.7% of the shares of the stock are
